Literature summary for 1.14.11.53 extracted from

Yang, S.; Wei, J.; Cui, Y.H.; Park, G.; Shah, P.; Deng, Y.; Aplin, A.E.; Lu, Z.; Hwang, S.; He, C.; He, Y.Y.
m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade (2019), Nat. Commun., 10, 2782 .

Search for more literature for 1.14.11.53

Application

Application	Comment	Organism
medicine	FTO level is increased in human melanoma. Knockdown of FTO increases m6A methylation in critical protumorigenic melanoma cell-intrinsic genes including PD-1, CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma	Homo sapiens
medicine	FTO nhances melanoma tumorigenesis in mice. Knockdown of FTO increases m6A methylation in critical protumorigenic melanoma cell-intrinsic genes including PD-1, CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma and sensitizes melanoma to anti-PD-1 treatment in mice	Mus musculus

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	Q9C0B1	-	-
Mus musculus	Q8BGW1	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
624 cell	-	Homo sapiens	-
624 cell	-	Mus musculus	-

General Information

General Information	Comment	Organism
physiological function	knockdown of FTO increases m6A methylation in critical protumorigenic melanoma cell-intrinsic genes including PD-1, CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma	Homo sapiens
physiological function	knockdown of FTO increases m6A methylation in critical protumorigenic melanoma cell-intrinsic genes including PD-1, CXCR4, and SOX10, leading to increased RNA decay through the m6A reader YTHDF2. Knockdown of FTO sensitizes melanoma cells to interferon gamma and sensitizes melanoma to anti-PD-1 treatment in mice	Mus musculus

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)